Name: OptiOral Care Oralopticeutical Bioregulator System
Brand: OptiOral Care
Availability: PreOrder

Question 1

What is Oralopticeutical™?

Accepted Answer

Oralopticeutical™ is the category coined by OptiOral Care — the precision intersection of oral health science and bioactive therapeutics. It sits above cosmetic and below drug. Every OptiOral Care product is formulated as a dietary supplement under 21 U.S.C. §321(ff) or as a professional-use topical preparation. No prescription is required.

Question 2

What are the active compounds in every product?

Accepted Answer

GHK (Gly-His-Lys), Ac-AEDG-NH₂, and Ac-KE-NH₂. GHK is naturally present in human saliva and declines more than 60% between age 20 and 60. Ac-AEDG-NH₂ is a novel dual-terminus modified analog studied directly in human gingival mesenchymal stem cells — p16 reduced 1.92x, p21 reduced 2.44x (p<0.01). Ac-KE-NH₂ modulates NFκB, the master inflammatory transcription factor driving alveolar bone resorption. All three compounds are in every product.

Question 3

Do I need a prescription to use these products?

Accepted Answer

No. The OptiOral Home line (Rinse, Paste, Strip, Mist) consists of dietary supplements — no prescription required. The Opti Series professional products are dispensed through licensed dental clinicians.

Question 4

What makes these different from chlorhexidine or Arestin?

Accepted Answer

Chlorhexidine and Arestin address only the microbial component of periodontal disease. They have zero mechanism for collagen synthesis, stem cell activation, or immune homeostasis. OptiOral Care products operate at the gene expression level — GHK stimulates collagen synthesis and modulates more than 4,000 human genes; Ac-AEDG-NH₂ reverses gingival stem cell senescence; Ac-KE-NH₂ suppresses NFκB-driven inflammatory destruction. These address a biological layer the existing market does not reach.

Question 5

What is the IP position?

Accepted Answer

OptiOral Care holds a portfolio of provisional patent applications covering novel Ac-X-NH₂ dual-terminus modified peptide bioregulator analogs. Patent pending across compositions of matter, formulation, and method-of-use domains. The compounds are non-injectable and outside the scope of expired prior art on injectable forms.

Question 6

Who is behind this?

Accepted Answer

OptiOral Care is a division of Atumnus Life Sciences, co-founded by Daniel Nowak (CTO) and Daniel William Dorsey (CEO). The company holds a portfolio of patent-pending bioregulator peptide IP and is launching the Oralopticeutical™ product category to bring published peptide science to the dental profession without a prescription barrier.

Be first.The system launches soon.

Be first.
The system launches soon.